Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1971 Dec;47(554):794–799. doi: 10.1136/pgmj.47.554.794

Current concepts of Parkinsonism.

J Pearce, I Pearce
PMCID: PMC2467372  PMID: 4945017

Full text

PDF
794

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. Long-term side-effects of levodopa. Lancet. 1971 Feb 20;1(7695):395–395. doi: 10.1016/s0140-6736(71)92226-4. [DOI] [PubMed] [Google Scholar]
  2. Bartholini G., Kuruma I., Pletscher A. 3-O-methyldopa, a new precursor of dopamine. Nature. 1971 Apr 23;230(5295):533–534. doi: 10.1038/230533a0. [DOI] [PubMed] [Google Scholar]
  3. Chase T. N. 5-hydroxytryptophan in parkinsonism. Lancet. 1970 Nov 14;2(7681):1029–1030. doi: 10.1016/s0140-6736(70)92837-0. [DOI] [PubMed] [Google Scholar]
  4. GARLAND H. G. Parkinsonism. Br Med J. 1952 Jan 19;1(4750):153–156. doi: 10.1136/bmj.1.4750.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Garland H., Pearce J. Neurological complications of carbon monoxide poisoning. Q J Med. 1967 Oct;36(144):445–455. [PubMed] [Google Scholar]
  6. Godwin-Austen R. B., Frears C. C., Bergmann S., Parkes J. D., Knill-Jones R. P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Aug 22;2(7669):383–385. doi: 10.1016/s0140-6736(70)90002-4. [DOI] [PubMed] [Google Scholar]
  7. Hughes R. C., Polgar J. G., Weightman D., Walton J. N. Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs. Br Med J. 1971 May 29;2(5760):487–491. doi: 10.1136/bmj.2.5760.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
  9. Lehmann J. Levodopa and depression in parkinsonism. Lancet. 1971 Jan 16;1(7690):140–140. doi: 10.1016/s0140-6736(71)90880-4. [DOI] [PubMed] [Google Scholar]
  10. Parkes J. D., Calver D. M., Zilkha K. J., Knill-Jones R. P. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970 Feb 7;1(7641):259–262. doi: 10.1016/s0140-6736(70)90634-3. [DOI] [PubMed] [Google Scholar]
  11. Pearce J., Aziz H., Gallagher J. C. Primitive reflex activity in primary and symptomatic Parkinsonism. J Neurol Neurosurg Psychiatry. 1968 Oct;31(5):501–508. doi: 10.1136/jnnp.31.5.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pearce J., Rao N. S. Amantadine in Parkinsonism. Lancet. 1970 Nov 21;2(7682):1091–1092. doi: 10.1016/s0140-6736(70)90332-6. [DOI] [PubMed] [Google Scholar]
  13. Rao N. S., Pearce J. Amantadine in Parkinsonism. An extended prospective trial. Practitioner. 1971 Feb;206(232):241–245. [PubMed] [Google Scholar]
  14. Weiner W., Harrison W., Klawans H. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism. Life Sci. 1969 Sep 1;8(17):971–976. doi: 10.1016/0024-3205(69)90428-7. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES